Leerink Swann believes that Momenta's (MNTA) partnership with Baxter (BAX) for the development of at least two biosimilar products will effectively combine the companies' strengths and enable parallel product development efforts. The firm maintains an Outperform rating on Momenta.
IMHO, the market and the sell-side analysts are a sleep at the wheel when considering MNTA's potential and likely will not awaken until mC is approved. I wonder if any analysts will up their views/target prices on MNTA now that an FoB partnership is inked and the risk of not signing an FoB deal has been removed.
Maybe they are waiting for the idiot Sapna to raise her target to 17 from 15. I am an Indian, but I hate these idiotic Indian analysts covering MNTA. Isn't that 4 of them? Ritu Baral has been the best of the worst
AI
